Theranostics for cancer imaging and treatment is a rapidly evolving science, and is being used in a multitude of oncologic diseases with immense potential to transform the cancer care landscape. As new molecular compounds are identified to target specific receptors, tissues, and tumour types, opportunities continue to expand for both diagnostic tracers and theranostic agents.